EN PL
Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis
 
More details
Hide details
 
Online publication date: 2007-12-20
 
 
Reumatologia 2007;45(6):407-414
 
KEYWORDS
ABSTRACT
Methotrexate (MTX) is the most frequently used drug in the treatment of rheumatoid arthritis. Oral administration has long been the standard way of administration. Generally it is well tolerated adverse some side effects (gastrointestinal) may lead to discontinuation of therapy. A significant lower bioavailability could be observed when MTX was administered orally while the bioavailability after subcutaneous application was similar to the intramuscular treatment. In some patients who did not tolerate or showed no significant clinical improvement under oral MTX, suppression of disease activity could be seen after switching to subcutaneous MTX. The subcutaneous injection is the only parenteral form which can easily be administered at home.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top